DBV Technologies shares slide toward their €1.57 support and lose 15.5% in one month
The Châtillon-based biotech extends its downward trend midway through the session, while the SBF 120 is slightly positive. The stock is trading well away from its moving averages, a few days after publishing its third-quarter accounts.
A stock more than 43% below its 200-day moving average and far from its support
The DBV Technologies stock falls 2.47% to €1.66, while the SBF 120 gains 0.4%. The stock is among the largest decliners in the index and has lost nearly 15.4% over one month. This decline places it 3% below its 20-day moving average and more than 43% below its 200-day moving average, a gap that reflects the extent of the sell-off underway since spring.
The RSI at 38 remains outside oversold territory, and the €1.57 support is less than 6% away from the current price. The third-quarter accounts, published on October 28, showed a net loss and doubt over the company's ability to continue as a going concern. Since then, the stock has remained under pressure, down 3.5% over the week.
FDA filing, financing and short positions down to 2.99%
At the time of the October 28 publication, the company stated that the marketing authorization application for the Viaskin Peanut patch in children aged 4 to 7 had been filed, with an FDA decision expected in the fourth quarter of 2026. It also mentioned a $50 million financing in ADS and a refreshed $150 million ATM program, while indicating that its capital requirements extend beyond the third quarter of 2027.
DBV is a single company listed in Paris (ordinary share, PEA-eligible) and on Nasdaq (ADS, at a ratio of one ADS for five shares).
On the short-selling side, four funds together hold a short position of 2.99% of the share capital according to the disclosures reviewed, compared with 4.53% thirty days earlier. This 1.54-point decline does not by itself signal a change in trend: the disclosures remain to be monitored, especially since the cumulative position remains significantly positive.
